acute lymphoblastic leukemia
Conditions
Interventions
Test group:TPO 300 U/kg ,subcutaneous injection once daily, period of treatment is equal to or less than 14 days. If the platelet count >50*10^9 / L, test two times continuously(not the same day),less
Sponsors
The Children's Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 17 Years
Inclusion criteria
Inclusion criteria: (1)Age: <18 years old, male or female; (2)Meet the diagnostic criteria of ALL, middle and high risk, after complete remission after induction chemotherapy, is under going consolidation therapy; (3)ECOG score <=2 points; (4)Life expectancy more than 12 weeks; (5)In the consolidation stage of treatment, bone marrow suppression is strong, leading to platelet count <80*10^9/L (test two times continuously), without intervention, platelet count is expected to be less than 20*10^9/L; (6)The serum creatinine level is less than or equal to 97 mol/l (1.5mg/dl), serum transaminase, bilirubin level lower than 2.5 times the upper limit of normal value; (7)No history of mental illness; (8)Children legal guardians' approval and signed informed consent form must be obtained.If the child could make decision to participate in the study, the child's approval and signed informed consent form also must be obtained.
Exclusion criteria
Exclusion criteria: (1)Using other drugs that could promote platelet production during the study, for example: Interleukin 11, TPO receptor agonist, Chinese medicine that could promote platelet production; (2)History of embolism; (3)Abnormal liver and kidney function, the serum transaminase and bilirubin equal to and more that 2.5 times of the upper limit of normal, Cr >97 mol/l (1.5mg/dl); (4)Severe organ dysfunction or disease, such as heart, liver, kidney, pancreas and serious diseases of nervous system and dysfunction; (5)At the same time with other tumor; (6)The child who could not adhere to medication in according to the study protocol; (7)The emergence of antiplatelet antibody in children (Platelet transfusion refractoriness, other manifestations of immune thrombocytopenic appears); (8)The investigator think that the child should not participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet count; | — |
Countries
China
Contacts
Public ContactWeiqun Xu
Outcome results
None listed